Allogene Therapeutics, Inc. (ALLO) Tops Q2 EPS by 6c, beats revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- Wall Street ends lower, off record highs, as Treasury yields climb
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Musk rules out TSMC role in Terafab operations; Intel gains
Tweet
Share
E-mail
Get Alerts ALLO Hot Sheet
Join SI Premium – FREE
Allogene Therapeutics, Inc. (NASDAQ: ALLO) reported Q2 EPS of ($0.53), $0.06 better than the analyst estimate of ($0.59). Revenue for the quarter came in at $40 thousand versus the consensus estimate of $13.47 thousand.
For earnings history and earnings-related data on Allogene Therapeutics, Inc. (ALLO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Some Said Inflation Risks Had Become More Skewed To Upside - FOMC Minutes
- Levi Strauss beats profit forecasts, shares edge higher
- NorthWestern Energy shares jump on Black Hills' Google data center deal
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
